Moreover, the latest guidelines from the American College of Cardiology and the American Heart Association for the management of HF include sST2 and Gal-3 as biomarkers for stratifying patients with acute and chronic HF (Yancy et al., 2017). This evidence concerns the gene LGALS3 and hydrops fetalis.